Piramal

Non-bank lender Piramal Finance on Friday reported that its net profit for the December quarter zoomed to Rs 401 crore from Rs 39 crore in the year-ago period. The company's managing director and chief executive, Jairam Sridharan, attributed the profit growth to a combination of factors, including growth in assets under management, expansion in net interest margins, control over operating expenses and lower credit costs. Its AUM jumped by over 23 per cent during the quarter, NIMs expanded by 0.50 per cent to 6.30 per cent, operating expenses grew by just 4 per cent and the provisions were up 36 per cent, as per a statement. The core net interest income grew 31 per cent to Rs 1,227 crore, while the other income was up 23 per cent at Rs 252 crore for the reporting quarter. The return on AUM stands at 1.9 per cent at present, and the company is aiming to take it further up to 3 per cent over the medium term, Sridharan said, adding that NIMs will have to expand by 0.30 per cent more to

Non-bank lender Piramal Finance plans to borrow up to USD 1 billion every year from foreign sources as it seeks to diversify its funding sources, a top official has said. The company has raised USD 350 million from IFC and ADB and is in advanced talks to secure another USD 150 million from a multilateral funding agency over the next three weeks, its Chief Executive and Managing Director Jairam Sridharan said. "We plan to continue to raise USD 500 million-1 billion from foreign sources across multiple routes every year," Sridharan said. In FY25, it had raised USD 800 million through external commercial borrowings and bond issue routes, but had not raised any money from foreign sources in FY26 given the rate cuts which made local borrowing cheaper, he added. The landed cost of funds in rupee terms, including hedging costs for the latest issuances, is in the range of 88.5 per cent, as against the incremental funding cost of 8.75-8.80 per cent for funding from domestic markets, He sai

The drugmaker's revenue fell 9% in Q2FY26 on below-par CDMO performance; company says it faced inconsistent funding in H1FY26

Year-to-date (Y-T-D), Piramal Pharma shares have lost 23 per cent, as compared to Sensex's rise of 5 per cent

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details

Piramal Pharma sold 20 per cent of its stake to Carlyle Group in June 2020, in a deal worth ₹3,523 crore

FY26, Kotak Institutional Equites believes, will likely see more broadbased growth across sectors. It has highlighted 6 stocks as high conviction ideas for an investor's portfolio

Says that their growth is led by innovation related work

The credit cost of the company increased to 1.9 per cent from 1.6 per cent in Q2 FY25

The uptick in Piramal Pharma share price came after domestic brokerage JM Financial initiated coverage with 'Buy' for a target price of Rs 340

Piramal Pharma is utilising a capex of about USD 85 million for various initiatives, including capacity expansion, maintenance and de-bottlenecking of CDMO sites, in the current fiscal, according to its Chairperson Nandini Piramal. The Mumbai-headquartered firm, which aims to cross USD 2 billion in revenue by FY30, has already invested around USD 30 million in the first half of the ongoing fiscal on the initiatives. "We expect the capex this year to be at a similar level as last year, which is about USD 85 million," Piramal told PTI in an interaction. A part of the capex is planned for the domestic market while some of it would also go into the US business, she added. "Some part of it, around USD 30 million, is maintenance capex, and the rest would go into capacity expansion in Telangana and Dahej (Gujarat) plants and also towards de-bottlenecking of some of the CDMO sites," Piramal noted. The company last week reported over four-fold increase in consolidated net profit at Rs 23 c

Piramal Pharma on Thursday reported over four-fold increase in consolidated net profit at Rs 23 crore for the second quarter ended September. The Mumbai-based company had reported a net profit of Rs 5 crore in the July-September quarter of last fiscal. Revenue from operations rose to Rs 2,242 crore in the second quarter as compared with Rs 1,911 crore in the year-ago period, Piramal Pharma said in a statement. "We continue our momentum of delivering healthy revenue growth accompanied by YoY EBITDA margin expansion. This has been primarily driven by consistent growth in our CDMO business which has witnessed a good pick-up in innovation-related work and on-patent commercial revenues," Piramal Pharma Chairperson Nandini Piramal said. To sustain this growth momentum and to capitalise on rising demand for sterile fill-finish capabilities, the company has announced a USD 80 million expansion plan at the Lexington facility which is expected to be completed by the FY27 end, she added. "In

Piramal Pharma aims to achieve over $2 billion in revenue by FY30, which implies 2 times growth in revenue compared with FY24

As many as 43.42 million equity shares, representing 3.3 per cent of total equity of the pharma company, had changed hands on the NSE till afternoon

The company said that the acquisition of shares aligns with the promoters' belief in its growth trajectory, further reflecting their trust in the company's business fundamentals

The retail AUM, which accounts for 72 per cent of the total AUM, increased by 43 per cent Y-o-Y to Rs 50,000 crore

Piramal Enterprises on Tuesday reported a 64 per cent decline in its June quarter net profit to Rs 181 crore, impacted because of a higher base due to a one-off item last year. The city-headquartered non-bank lender had reported a consolidated net profit of Rs 509 crore in the year-ago period. Its managing director and chief executive Jairam Sridharan said the year-ago performance included a Rs 850 crore benefit from a stake sale in a Shriram Group entity, and added that the performance has been stable in the reporting quarter this year. The core net interest income grew 18 per cent to Rs 807 crore on the back of a 10 per cent increase in the overall assets under management to Rs 70,576 crore, while the net interest margin narrowed to 6.7 per cent from 7.3 per cent in the year-ago period. Sridharan said disbursements were impacted in the June quarter due to regulatory changes around fair practices but exuded confidence that the company will be able to meet its FY25 target of 15 per

In Q4FY24, Piramal Pharma reported a 102 per cent Year-on-Year (YoY) surge in Profit After Tax (PAT), totaling Rs 101.27 crore

On a sequential basis, the company's profit jumped more than nine-fold

The funding will be utilised to improve Biodeal's infrastructure and production capacity